TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27138769

Group type: EXPERIMENTAL
Intervention: Familial-risk group (two FDR with colorectal cancer)
Number of subjects: 8498

Group type: EXPERIMENTAL
Intervention: Familial-risk group (one FDR diagnosed at ≥60 y)
Number of subjects: 8498

Group type: EXPERIMENTAL
Intervention: Familial-risk group (one FDR diagnosed at <60 y)
Number of subjects: 8498

Group type: EXPERIMENTAL
Intervention: Men (general population)
Number of subjects: 8498

Group type: EXPERIMENTAL
Intervention: Women (general population)
Number of subjects: 8498

Group type: COMPARATOR
Intervention: Average-risk group
Number of subjects: 8498
Study: 24105403

Group type: EXPERIMENTAL
Intervention: Automated risk calculations for postoperative nausea and vomiting (PONV)
Number of subjects: 11613

Group type: COMPARATOR
Intervention: Care-as-usual (no automated risk calculations)
Number of subjects: 11613
Study: 22090065

Group type: EXPERIMENTAL
Intervention: 40% O(2) during contractions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% O(2) during recovery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Room air (normoxia) throughout
Number of subjects: 10
Study: 19904553

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 325
Study: 19032254

Group type: EXPERIMENTAL
Intervention: Standard surgical method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minitrach II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quicktrach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melker kit
Number of subjects: 0
Study: 15742599

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14657528

Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.0 mg/m2
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.3 mg/m2
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.3 mg/m2 (in phase II study)
Number of subjects: 256
Study: 10390554

Group type: EXPERIMENTAL
Intervention: 20 mg of dicyclomine chlorhydrate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 80 mg of dicyclomine chlorhydrate
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-drug control group
Number of subjects: 48
Study: 8654625

Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment (6 SC implants of 3.6 mg goserelin acetate depot every 28 days for 6 months)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 53
Study: 8485328

Group type: EXPERIMENTAL
Intervention: Total nutrient admixture (TNA) at the rate of 4‐5 g lipid/h for 5‐9 days (mean 6.7 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Filtration of TNA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no filtration)
Number of subjects: 16
Study: 3816916

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 19
Study: 31727561

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting lymph node invasion (LNI) after RALP
Number of subjects: 1654
Study: 29757893

Group type: EXPERIMENTAL
Intervention: Early initiated everolimus
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (no everolimus)
Number of subjects: 192
Study: 24359045

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 22827935

Group type: EXPERIMENTAL
Intervention: Rehabilitative sports group exercise program for prostate cancer patients, conducted for 15 months starting 8-12 weeks after prostatectomy or combination therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no participation in the intervention).
Number of subjects: 0
Study: 21375023

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diovan (80 mg)
Number of subjects: 80
Study: 18037738

Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin, clopidogrel, cilostazol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual therapy (aspirin and clopidogrel)
Number of subjects: 60
Study: 16077266

Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory blood pressure monitoring (first and second recordings)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory blood pressure monitoring (second and third recordings)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory blood pressure monitoring (normotensive patients)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Continuous percentage values of declines in pressure during sleep
Number of subjects: 101
Study: 12406382

Group type: EXPERIMENTAL
Intervention: TiN-coated instruments (Group B.1, B.2, B.3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Uncoated instruments (Group A.1, A.2, A.3)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control instruments (A.C/B.C)
Number of subjects: 96
Study: 10598301

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study: 7697307

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2; 6 x 10(6) IU)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN alpha; 2 x 10(7) U)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Interferon beta (IFN beta; 6 x 10(6) U)
Number of subjects: 70
Study: 2548967

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole
Number of subjects: 78

Group type: COMPARATOR
Intervention: 500 mg ultramicronized griseofulvin
Number of subjects: 78
Study: 1099692

Group type: EXPERIMENTAL
Intervention: Three antimalarial drugs
Number of subjects: 744

Group type: COMPARATOR
Intervention: Local population (control)
Number of subjects: 744
Study: 28391452

Group type: EXPERIMENTAL
Intervention: PEERS® Social Skills Intervention
Number of subjects: 177
Study: 26641243

Group type: EXPERIMENTAL
Intervention: GM-CSF (250 μg/m2/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Influenza vaccination (Mutagrip 0.5 ml/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24060253

Group type: EXPERIMENTAL
Intervention: Breast cancer education program (details not specified)
Number of subjects: 209
Study: 21569994

Group type: EXPERIMENTAL
Intervention: Sunitinib plus paclitaxel
Number of subjects: 485

Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 485
Study: 19092693

Group type: COMPARATOR
Intervention: C(AFF) + NF
Number of subjects: 7

Group type: COMPARATOR
Intervention: WAT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: C(AFF) + WAT
Number of subjects: 7

Group type: COMPARATOR
Intervention: CES
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: C(AFF) + CES
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: C(AFF)
Number of subjects: 7
Study: 16837720

Group type: EXPERIMENTAL
Intervention: beta‐arteether
Number of subjects: 138

Group type: COMPARATOR
Intervention: alpha/beta‐arteether
Number of subjects: 138
Study: 12571166

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 0
Study: 11482712

Group type: EXPERIMENTAL
Intervention: Phase‐contrast cine MR angiography
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (asymptomatic normals)
Number of subjects: 230
Study: 9113180

Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O
Number of subjects: 62

Group type: COMPARATOR
Intervention: Propofol-N2O
Number of subjects: 62
Study: 8364348

Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 3721047

Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia (L.E.A.)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (i.v. infusion of Hydralazine and MgSO4)
Number of subjects: 52
Study: 30354704

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Consensus OH
Number of subjects: 1094
Study: 26674764

Group type: EXPERIMENTAL
Intervention: Zinc-biofortified rice (hydroponically enriched with (70)Zn)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control rice fortified with (70)ZnSO4
Number of subjects: 16
Study: 24770616

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RiPoC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22421496

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TNE)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard endoscopy (SE)
Number of subjects: 95
Study: 20153122

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 38
Study: 18267181

Group type: EXPERIMENTAL
Intervention: CT screening for lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest radiography and sputum cytology
Number of subjects: 0
Study: 16087821

Group type: EXPERIMENTAL
Intervention: Risedronate sodium (2.5 mg daily) plus ergocalciferol (1000 IU) and calcium (1200 mg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo plus ergocalciferol (1000 IU) and calcium (1200 mg)
Number of subjects: 500
Study: 12700718

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam (DZP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (DZP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10582134

Group type: EXPERIMENTAL
Intervention: HD-EPI 120 mg/m2 + CP 60 mg/m2
Number of subjects: 228

Group type: COMPARATOR
Intervention: VNR 25 mg/m2 + CP 60 mg/m2
Number of subjects: 228
Study: 8729714

Group type: EXPERIMENTAL
Intervention: Self-Examination Therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Current Events comparison group
Number of subjects: 28
Study: 1896818

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 10
Study: 7038354

Group type: EXPERIMENTAL
Intervention: Bazalin (yellow labeled tubes containing fluocinolone acetonide 0.025%, leucobitupal 5% and salicylic acid 3%)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Desoximetasone (red labelled tubes)
Number of subjects: 22
Study: 31743184

Group type: EXPERIMENTAL
Intervention: Incentive-based game therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29943647

Group type: EXPERIMENTAL
Intervention: WhatsApp application for diabetes education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 0
Study: 27863598

Group type: EXPERIMENTAL
Intervention: Simulated laughter programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 24343388

Group type: EXPERIMENTAL
Intervention: Activated chlorine dioxide (CD) wound irrigation
Number of subjects: 193

Group type: COMPARATOR
Intervention: Normal saline (NS) wound irrigation
Number of subjects: 193
Study: 23174912

Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab (6 cycles) followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression
Number of subjects: 394
Study: 19476471

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg once daily
Number of subjects: 0
Study: 17459031

Group type: EXPERIMENTAL
Intervention: Single posterior subtenon injection of triamcinolone acetonide (40 mg in 1 ml) plus sham eyedrops (prednisolone acetate 1% vehicle)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Posterior subtenon sham injection (1 ml balanced salt solution) plus prednisolone acetate 1% eyedrops
Number of subjects: 40
Study: 15295955

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg with hydrocodone 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg alone
Number of subjects: 12
Study: 11436942

Group type: EXPERIMENTAL
Intervention: 2% ibopamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5% dapiprazole
Number of subjects: 45
Study: 9626917

Group type: EXPERIMENTAL
Intervention: Desmin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 17
Study: 7882821

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 3346483

Group type: EXPERIMENTAL
Intervention: 200 mg of theophylline in 19.9 mg of ethylenediamine (TE200)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 351 mg of theophylline in 35 mg of ethylenediamine (TE351)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 mg of theophylline in 300 mg of propxyphylline and 300 mg of diprophylline (TPD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 11
Study: 29270914

Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB) with 20 mL of levobupivacaine 0.25% and epinephrine 5 µg·mL‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined infraclavicular-suprascapular blocks (ICB-SSB) with 20 mL of levobupivacaine 0.25% and 10 mL for SSB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 40
Study: 26922549

Group type: EXPERIMENTAL
Intervention: Intensive statin treatment (rosuvastatin 20‐40 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Less aggressive statin treatment (simvastatin 20‐40 mg daily)
Number of subjects: 38
Study: 24926525

Group type: EXPERIMENTAL
Intervention: Test food (carbohydrate-protein bar with ewe-goat whey)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Reference food
Number of subjects: 9
Study: 22790642

Group type: EXPERIMENTAL
Intervention: Once-daily tadalafil 5 mg (with possible down-titration to 2.5 mg)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 21905252

Group type: EXPERIMENTAL
Intervention: Higher scores on scales measuring beliefs that physical activity is beneficial for their disease
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Higher scores on scales measuring motivation for physical activity participation
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Worries about physical activity participation
Number of subjects: 185
Study: 18214942

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (IF) 2 mg/kg nebulized by hood three times daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo nebulized by hood three times daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (IF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17064621

Group type: EXPERIMENTAL
Intervention: RFA therapy combined with suture and ligation surgery (SL group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RFA therapy without suture and ligation surgery (non-SL group, n = 15)
Number of subjects: 30
Study: 12488118

Group type: EXPERIMENTAL
Intervention: sleep hygiene + stimulus control
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: sleep hygiene + relaxation tape
Number of subjects: 55

Group type: COMPARATOR
Intervention: waiting-list condition
Number of subjects: 55
Study: 10397519

Group type: EXPERIMENTAL
Intervention: One stage full-mouth disinfection (scaling and root planing of 4 quadrants within 24 hours, application of chlorhexidine to all intra-oral niches, rinsing twice daily with 0.2% chlorhexidine solution, and spraying tonsils with 0.2% chlorhexidine spray for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy (scaling and root planing per quadrant at 2-week intervals and standard oral hygiene instructions)
Number of subjects: 40
Study: 8676224

Group type: EXPERIMENTAL
Intervention: LA + V used (group 1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: LA + V not used (group 2)
Number of subjects: 34
Study: 1829902

Group type: EXPERIMENTAL
Intervention: 200 mg UK 79300
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 mg UK 79300
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: UK 79300 (both dosages)
Number of subjects: 14
Study: 6393827

Group type: EXPERIMENTAL
Intervention: Anesthelec (transcutaneous cranial electrical stimulation with Limoge currents)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anesthelec
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 20
Study: 31615134

Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Standard infant formula (SF)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 170
Study: 29581034

Group type: EXPERIMENTAL
Intervention: Palliative care preference (defined as comfort care focusing on quality of life)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 383
Study: 26681800

Group type: EXPERIMENTAL
Intervention: TPF (Cisplatin, 5-fluorouracil, Docetaxel)
Number of subjects: 213

Group type: COMPARATOR
Intervention: PF (Cisplatin, 5-fluorouracil)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 213

Group type: COMPARATOR
Intervention: PF
Number of subjects: 213
Study: 24641687

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23174049

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (4 U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (6 U)
Number of subjects: 0
Study: 20537958

Group type: EXPERIMENTAL
Intervention: 0.2% nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.4% nifedipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16965823

Group type: EXPERIMENTAL
Intervention: Automatic scoring method using two-channel EOG with amplitude criteria and beta power exclusion
Number of subjects: 265

Group type: COMPARATOR
Intervention: Standard visual sleep scoring based on EOG, central EEG, and submental EMG
Number of subjects: 265
Study: 16340099

Group type: EXPERIMENTAL
Intervention: Gait and step perturbation training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 12359989

Group type: EXPERIMENTAL
Intervention: Irbesartan (n = 49)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Atenolol (n = 53)
Number of subjects: 102
Study: 10333643

Group type: EXPERIMENTAL
Intervention: Serological diagnosis of parasitosis using immunoelectrophoresis, Elisa, or Western blot
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Blood cell count
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral transmission of strongyloidiasis
Number of subjects: 22
Study: 7710623

Group type: EXPERIMENTAL
Intervention: Bone graft and implant placement in the routine group (20 patients)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bone graft and implant placement in the development group (10 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bone graft and implant placement (both groups)
Number of subjects: 30
Study: 2568784

Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0
Study: 901625

Group type: EXPERIMENTAL
Intervention: BM 15.075 (0.2 g t.i.d.)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Clofibate (0.5 g t.i.d.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BM 15.075 (0.2 g t.i.d.) and Clofibate (0.5 g t.i.d.)
Number of subjects: 29
Study: 30042699

Group type: EXPERIMENTAL
Intervention: Targeted treatment (CBT modules focusing on craving, positive expectancy, or impulsivity)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Targeted craving module
Number of subjects: 379

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 379
Study: 27151908

Group type: EXPERIMENTAL
Intervention: Automated delivery system (Navigator Delivery System; Carticept Medical, Inc)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard syringe injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both injection techniques
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Automated delivery system
Number of subjects: 40
Study: 25534167

Group type: COMPARATOR
Intervention: 3-dimensional conventional tangential fields (TFs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: tangential intensity‐modulated therapy (T‐IMRT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 fields IMRT (4F‐IMRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: single arc volumetric‐modulated arc therapy (S‐VMAT)
Number of subjects: 30
Study: 23538980

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery program
Number of subjects: 119
Study: 20410150

Group type: EXPERIMENTAL
Intervention: Sit-to-stand training (15 minutes each session, in addition to 30 minutes of general physical therapy three times a week for four weeks)
Number of subjects: 32
Study: 18217968

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery (LAS)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 331
Study: 16403594

Group type: EXPERIMENTAL
Intervention: Isokinetic knee extensor strength testing at 14 angular velocities in hemiparetic group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isokinetic knee extensor strength testing at 14 angular velocities in control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Measurement error for hemiparetic subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Measurement error for control subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smallest real difference for hemiparetic subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Smallest real difference for control subjects
Number of subjects: 30
Study: 12852929

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10780125

Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (CM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM
Number of subjects: 42
Study: 8981202

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 1736568

Group type: EXPERIMENTAL
Intervention: Taurine (5 gm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6582585

Group type: EXPERIMENTAL
Intervention: Combined granulocyte and platelet transfusions
Number of subjects: 23